Uracil News and Research

RSS

Pre-op PET/CT predicts stage I NSCLC adjuvant chemotherapy benefit

Preoperative imaging could help guide the use of postoperative adjuvant chemotherapy in patients with early non-small-cell lung cancer, Japanese researchers believe.

21 Aug 2014

Researchers identify steps by which cell removes RNA from cytoplasm

RNA encodes the proteins that play a key role in cellular reproduction, but the manner in which cells regulate its removal once these proteins are synthesized remains a mystery. One piece of this mystery has been solved as researchers at the University of North Carolina at Chapel Hill who have identified the steps by which a cell removes RNA from the cytoplasm.

21 Mar 2014

Researchers develop computational model to accurately simulate complex twists of RNA

A computational model developed by researchers at Rensselaer Polytechnic Institute is the first to accurately simulate the complex twists of a short sequence of RNA as it folds into a critical hairpin structure known as a "tetraloop."

17 Sep 2013

Novel way to dramatically raise potency of drug candidates targeting RNA

Scientists from the Jupiter campus of The Scripps Research Institute (TSRI) have shown a novel way to dramatically raise the potency of drug candidates targeting RNA, resulting in a 2,500-fold improvement in potency and significantly increasing their potential as therapeutic agents.

6 Aug 2013

TSRI scientists identify small molecules to control genetic defect responsible for muscular dystrophy

For the first time, scientists from the Florida campus of The Scripps Research Institute have identified small molecules that allow for complete control over a genetic defect responsible for the most common adult onset form of muscular dystrophy.

28 Jun 2013

Prior chemotherapy extends postpalliative survival in pancreatic cancer

Patients with locally advanced pancreatic cancer have a more favorable prognosis after palliative chemoradiotherapy if they have previously been treated with a gemcitabine-based therapy, say Danish researchers.

14 Jun 2012

Scientists design compounds that act against myotonic dystrophy type 1 RNA

While RNA is an appealing drug target, small molecules that can actually affect its function have rarely been found. But now scientists from the Florida campus of The Scripps Research Institute have for the first time designed a series of small molecules that act against an RNA defect directly responsible for the most common form of adult-onset muscular dystrophy.

23 Feb 2012

Gilead enters agreement for Pharmasset acquisition

Gilead Sciences, Inc. and Pharmasset, Inc. announced today that the companies have signed a definitive agreement under which Gilead will acquire Pharmasset for $137 per share in cash.

21 Nov 2011

Inefficiency of activation-induced deoxycytidine deaminase is good for the immune system

Why is antibody diversity important? Think about it like this, said Myron Goodman, who is an author on the paper: "Why don't you die when I sneeze? It's because you have a powerful immune system. And the way to get a decent immune system is for your body to have a way to respond to insults it has never seen before."

28 Jun 2011

Pharmasset receives U.S. patent titled 'Nucleoside Phosphoramidate Prodrugs'

Pharmasset, Inc. announces that the United States Patent and Trademark Office has issued U.S. patent 7,964,580 titled "Nucleoside Phosphoramidate Prodrugs".

22 Jun 2011

NICE draft guidance rejects cancer drug bevacizumab

The National Institute for Health and Clinical Excellence (NICE) has released draft guidance for cancer drug bevacizumab (Avastin).

25 Aug 2010

Researchers find compound that reverses type 1 myotonic dystrophy

A compound already used to treat pneumonia could become a new therapy for an inherited muscular wasting disease, according to researchers at the University of Oregon and the University of Rochester School of Medicine and Dentistry in New York.

7 Nov 2009

A quantum dot-based method for analysis of DNA methylation

One of the earliest events that changes a normal cell into a malignant one is known as deoxyribonucleic acid (DNA) hypermethylation, a biochemical alteration that inactivates critical tumor-suppressor genes.

21 Jul 2009

Research brings quick, precise view of cell development and gene expression

A team of University of Oregon biologists, using fruit flies, has created a way to isolate RNA from specific cells, opening a new window on how gene expression drives normal development and disease-causing breakdowns.

18 May 2009

VioQuest Pharmaceuticals issued new U.S. patent for Lenocta

VioQuest Pharmaceuticals today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases.

26 Aug 2008